On the Record · PRA Health Sciences
PRA Health Sciences acquisitions, on the record
The businesses PRA Health Sciences bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Symphony HealthWord for word“In September 2017, we acquired Symphony Health, which has enhanced our ability to serve customers throughout the clinical research process with technologies that provide data and analytics.” 10-K for 2018 | acquisition | — | — |
Parallel 6, Inc.Word for word“Additionally, in May 2017, we acquired Parallel 6, Inc., or Parallel 6, which has allowed us to offer our customers technologies that provide improved efficiencies by reducing study durations and costs through integrated operational management.” 10-K for 2018 | acquisition | May 2017 | — |
Takeda PRA Development Center KKWord for word“Acquisition of Takeda PRA Development Center KK, net of cash acquired — 2,680 — Acquisition of Takeda Pharmaceutical Data Services, Ltd., net of cash acquired — ( 142 ) — Acquisition of Nextrials, Inc., net of cash acquired — — ( 4,268 ) Distributions from unconsolidated joint ventures — — 3,700 Net cash used in investing activities ( 55,473 ) ( 687,420 ) ( 34,614 ).” 10-K for 2018 | acquisition | — | — |
Takeda Pharmaceutical Data Services, Ltd.Word for word“Acquisition of Takeda Pharmaceutical Data Services, Ltd., net of cash acquired — ( 142 ) — Acquisition of Nextrials, Inc., net of cash acquired — — ( 4,268 ) Distributions from unconsolidated joint ventures — — 3,700 Net cash used in investing activities ( 55,473 ) ( 687,420 ) ( 34,614 ).” 10-K for 2018 | acquisition | — | — |
Nextrials, Inc.Word for word“Acquisition of Nextrials, Inc., net of cash acquired — — ( 4,268 ) Distributions from unconsolidated joint ventures — — 3,700 Net cash used in investing activities ( 55,473 ) ( 687,420 ) ( 34,614 ).” 10-K for 2018 | acquisition | — | — |
WuXiPRA joint ventureWord for word“Additionally, capital expenditures increased by $28.2 million compared to the prior year, which is partially offset by $3.7 million received from the sale of our ownership stake in the WuXiPRA joint venture during the year ended December 31, 2016.” 10-K for 2018 | divestiture | during the year ended December 31, 2016 | $3.7 million |
Symphony Health Solutions CorporationWord for word“On September 6, 2017, the Company acquired all of the outstanding equity interest of Symphony Health, a provider of data and analytics to help professionals understand the full market lifecycle of products offered for sale by companies in the pharmaceutical industry, for $ 686.9 million .” 10-K for 2019 | acquisition | — | $ 686.9 million |
Takeda's 50% interest in the TDC joint venture (Takeda PRA Development Center KK)Word for word“On May 31, 2019, per the terms of the agreement, the TDC joint venture dissolved and the Company acquired Takeda's interest for $4.1 million.” 10-K for 2019 | agreed acquisition | On May 31, 2019 | $4.1 million |
Care Innovations, Inc.Word for word“$1.3 million of expenses related to the acquisition of Care Innovations, Inc., which closed on January 7, 2020.” 10-K for 2019 | acquisition | closed on January 7, 2020 | — |
Takeda joint venture (TDC) noncontrolling interestWord for word“Accordingly, the Company accounted for the $ 5.4 million contribution to the TDC joint venture as a business combination and consolidated the VIE in its financial statements with a noncontrolling interest for the 50 % portion owned by Takeda.” 10-K for 2019 | acquisition | — | $ 5.4 million |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2016-12-31 | $0 | — |
| 2018-12-31 | $0 | — |
| 2019-12-31 | $0 | — |
| 2020-12-31 | $158.8 million | $175.3 million |
Deal filings since 2016
- 2021-07-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-07-01 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2021-02-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-12-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-10-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-09-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-09-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-08-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-06-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-12-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-09-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-09-11 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-08-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-08-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-12-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-11-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-05-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-03-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-03-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from PRA Health Sciences’s annual reports (10-K for 2020, 10-K for 2019, 10-K for 2018) and the financial data it files with the SEC, as of 2021-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.